Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $479.2 million.

  • Apellis Pharmaceuticals' Cash & Equivalents rose 2074.67% to $479.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.2 million, marking a year-over-year increase of 2074.67%. This contributed to the annual value of $411.3 million for FY2024, which is 1711.49% up from last year.
  • Apellis Pharmaceuticals' Cash & Equivalents amounted to $479.2 million in Q3 2025, which was up 2074.67% from $370.0 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Cash & Equivalents peaked at $765.1 million during Q1 2023, and registered a low of $265.4 million during Q1 2021.
  • Its 5-year average for Cash & Equivalents is $459.0 million, with a median of $411.3 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 13864.83% in 2022, then plummeted by 5740.03% in 2024.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Cash & Equivalents stood at $640.2 million in 2021, then dropped by 13.81% to $551.8 million in 2022, then plummeted by 36.36% to $351.2 million in 2023, then grew by 17.11% to $411.3 million in 2024, then increased by 16.51% to $479.2 million in 2025.
  • Its Cash & Equivalents was $479.2 million in Q3 2025, compared to $370.0 million in Q2 2025 and $358.4 million in Q1 2025.